Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914475 | 1.00 | TK1 (0.51) | TK1LMNATSHRALBPKM | |
| SCHEMBL31652832 | 0.88 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL31653051 | 0.88 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL913904 | 0.88 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL12942599 | 0.88 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL31652938 | 0.88 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL913905 | 0.88 | TK1 (0.55) | TK1ALBPKM | |
| SCHEMBL914833 | 0.86 | TK1 (0.48) | TK1 | |
| SCHEMBL9548636 | 0.83 | TK1 (0.52) | TK1LMNATSHRALBPKM | |
| SCHEMBL9548632 | 0.83 | TK1 (0.52) | TK1LMNATSHRALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937825-B1 | MODIFIED 4'-NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD PHARMASSET LLC (US) | 2016-12-21 | — | — | EP | claimed |
| US-8569478-B2 | Modified 4′-nucleosides as antiviral agents | GILEAD PHARMASSET LLC (US) | 2013-10-29 | — | — | US | claimed |
| US-20110021454-A1 | MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-3159351-A2 | MODIFIED 3'-AZIDO-4'-ETHYNYL-NUCLEOSIDES AS ANTIVIRAL AGENTS | Gilead Pharmasset LLC (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-1937825-B1 | MODIFIED 4'-NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD PHARMASSET LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-8569478-B2 | Modified 4′-nucleosides as antiviral agents | GILEAD PHARMASSET LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110021454-A1 | MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-1937825-A2 | MODIFIED 4'-NUCLEOSIDES AS ANTIVIRAL AGENTS | Pharmasset, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007038507-A2 | MODIFIED 4'-NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021454-A1 | MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, PNP, SAMHD1 | TK1 93/4885LMNA 983/4885TSHR 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.